Drug intelligence / Profile preview

SU0547

Development stage: Unknown
Lead developer: Stanford University

Overview

SU0547: sourced facts only. name: "SU0547 activates SMUG1 by 347 ± 50% in vitro at 100 nM, with an AC50 of 2.55 ± 0.62 µM." [DOI:10.1158/1538-7445.am2024-4777]; target: "SU0547 activates SMUG1 by 347 ± 50% in vitro at 100 nM, with an AC50 of 2.55 ± 0.62 µM." [DOI:10.1158/1538-7445.am2024-4777]; developer: "1Stanford University, Stanford, CA." [DOI:10.1158/1538-7445.am2024-4777]; stage: "In all five human cancer cell lines tested, SU0547 caused the cells to become significantly more resistant to 5-hmdU by factors of 2.1 to 5.3-fold." [DOI:10.1158/1538-7445.am2024-4777]

Targets

SMUG1 (Single-strand selective monofunctional uracil DNA glycosylase)

Beyond the preview

Go deeper on SU0547.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SU0547.